Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Deasy
    Deasy
  3. Adusumilli
    Adusumilli
  4. Thor
    Thor
  5. Giralt
    Giralt
  6. Jones
    Jones
  7. Hultcrantz
    Hultcrantz
  8. Leitao
    Leitao
  9. Scordo
    Scordo
  10. Shah
    Shah

Groups

  1. Sloan Kettering Institute Postdocs (1173)
  2. Department of Medicine (452)
  3. GSK Faculty (362)
  4. Surgery (352)
  5. Survivorship Research (328)
  6. Graduate Medical Education (271)
  7. Radiation Oncology, Department of (250)
  8. Solid Tumor Oncology Division (244)
  9. Department of Pathology and Laboratory Medicine (222)
  10. Hematologic Malignancies, Division of (222)
Search Within
  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (524)
  2. Journal Article (523)
  3. Review (72)
  4. Book Section (22)
  5. Editorial (12)
  6. Correspondence (9)
  7. Research Letter (5)
  8. Conference Paper (4)
  9. Guidelines (2)
Groups
  1. Sloan Kettering Institute Postdocs (1173)
  2. Department of Medicine (452)
  3. GSK Faculty (362)
  4. Surgery (352)
  5. Survivorship Research (328)
  6. Graduate Medical Education (271)

More Groups

People
  1. Nadeem Abu-Rustum (84)
  2. Joseph Deasy (83)
  3. Prasad Adusumilli (74)
  4. Maria Thor (73)
  5. Andreas Rimner (72)
  6. Sergio Giralt (68)

More People

Years
  1. 2025 (29)
  2. 2024 (138)
  3. 2023 (116)
  4. 2022 (121)
  5. 2021 (106)
  6. 2020 (94)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (222)
  2. Journal of Thoracic Oncology (133)
  3. Gynecologic Oncology (96)
  4. Clinical Lymphoma, Myeloma and Leukemia (68)
  5. Biology of Blood and Marrow Transplantation (65)
  6. Radiotherapy and Oncology (54)

More Publications

Results (1173)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Increased WEE1 expression is predictive of short progression-free survival, independent of standard prognostic factors in multiple myeloma
    Meeting Abstract

    Simhal, A.; Firestone, R.; Oh, J. H.; Norton, L.; Usmani, S.; Deasy, J.; Maclachlan, K.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
    Meeting Abstract

    Costa, A.; Dhakal, B.; Hultcrantz, M.; Bal, S.; Chuah, H.; Kaufman, J. L.; Kazandjian, D.; Nathwani, N.; Royle, G.; Sborov, D. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save